22^nd International Conference on Cancer Biology and Cell Science September 19-20, 2024 Paris, France

Cancer Biology 2024 will be useful to participants from both the Industry and Academia working in all the domains of Health care sectors, all other target audience includes:

• Researchers
• Scientists
• Health care experts
• Epidemiologists
• Physicians
• Nurse practitioners
• Health care analysts
• Business delegates
• Young Researchers
• Advertising and Promotion Agency Executives
• Professionals in media sector
• Professors
• Surgeons
• Fellowship Holders
• Surgical Technicians
• Anesthesiologists
• Medicals Students
• Healthcares and pharmaceutical companies

The 22nd International Conference on Cancer Biology and Cell Science offers a premier platform for researchers, clinicians, industry professionals, and policymakers to convene, collaborate, and catalyze advancements in the fight against cancer. Set against the backdrop of picturesque this conference promises to be a pivotal event in shaping the future of cancer research and diagnostics.

Top Reasons to Attend:

1. Cutting-Edge Research Presentations: Immerse yourself in a comprehensive program featuring presentations from leading experts in the field of oncology and Cell Science. 
2. Networking Opportunities: Connect with a diverse community of professionals including researchers, clinicians, industry leaders, and policymakers.
3. Interactive Workshops and Symposia: Engage in interactive workshops and symposia designed to deepen your understanding of key topics such as precision medicine, immunotherapy, early detection strategies, and emerging technologies in cancer diagnostics.
4. Poster Presentations: Showcase your own research findings through poster presentations and receive valuable feedback from peers and experts in the field. 
5. Industry Insights and Exhibits: Explore the latest advancements in cancer diagnostics, therapeutics, and technology through exhibits and presentations by leading industry partners. 
6. Continuing Education Credits: Earn valuable continuing education credits by attending accredited sessions led by esteemed professionals. 
7. Global Perspective: Gain a global perspective on cancer research and diagnostics by interacting with participants from around the world. Learn about regional challenges, innovative approaches, and best practices that can inform and enrich your own work.
8. Inspiration and Motivation: Be inspired by keynote speeches, panel discussions, and success stories from individuals who are at the forefront of cancer research and diagnostics. 

Conferences invite all the actors around the world to fix at the 22nd International Conference on Cancer Biology and cell science that goes to be listed on September 19–20, 2024, in Paris, France, which is suitable to embrace keynote shows, Oral addresses, Bill shows, and Exhibitions. Cancer Biology 2024 may be an especially well-designed cluster conference. The main focus of the conference is “Advancement of Cancer Biology and Eradication of Cancer,” which covers a large vary of critically necessary sessions.

Research and Development

Scientific improvements in understanding rare cancers that lead to new rectifiers and a probability  biomedical Eco-system that provides a backing and support for R&D, especially among arising biopharma companies, have redounded in a channel of nearly implicit cancer treatments, over 75 since 2015.

Bringing Scientific Advances to Cancer Cases

Access to drugs has been steadily increasing, and 9.2 billion Defined daily doses were delivered encyclopedically in 2020, but variability across countries remains high, and the use of prophetic biomarkers to effectively deliver perfection drugs to those who'll profit from them remains variable across cancer types and countries.

Spending on Oncology Medicines

The swell in invention treatments in recent times, accompanied by a strong focus across health systems to increase early opinion and expanded patient access to treatments, has redounded in global spending on oncology medicines, reaching $164 billion in 2020 and an estimated $269 billion by 2025 indeed as periodic growth rates ease to about 10. Exhibition 52: Global oncology spending growth to exceed $260 billion by 2025, with growth decelerating to 9–12 from biosimilar savings.

1. Cancer Science
2. Oncogenomics
3. Skin Cancer
4. Breast cancer
5. Prevention
6. Chemotherapy
7. Advance in radiation therapy
8. Cell Signaling and Cell Death
9. Innovations of Cancer
10. Gastric Cancer stem cells
11. Quality of Life & Supportive Care
12. Vaccines and Biomarkers
13. Molecular Pathology
14. Diagnostic Challenges
15. Breast Imaging
16. Pathological Assessment of Breast Reconstruction
17. Multidisciplinary Approach to Breast Pathology
18. Pathology of Triple-Negative Breast Cancer

For abstract submission

For registration

Conferences invite all the actors around the world to fix at the 22nd International Conference on Cancer Biology and Therapeutics that goes to be listed on Septembert 19–20, 2024, in Paris, France, which is suitable to embrace keynote shows, Oral addresses, Bill shows, and Exhibitions. Cancer Biology 2024 may be an especially well-designed cluster conference. The main focus of the conference is “Advancement of Cancer Biology and Eradication of Cancer,” which covers a large vary of critically necessary sessions.

Research and Development

Scientific improvements in understanding rare cancers that lead to new rectifiers and a probability  biomedical Eco-system that provides a backing and support for R&D, especially among arising biopharma companies, have redounded in a channel of nearly implicit cancer treatments, over 75 since 2015.

Bringing Scientific Advances to Cancer Cases

Access to drugs has been steadily increasing, and 9.2 billion Defined daily doses were delivered encyclopedically in 2020, but variability across countries remains high, and the use of prophetic biomarkers to effectively deliver perfection drugs to those who'll profit from them remains variable across cancer types and countries.

Spending on Oncology Medicines

The swell in invention treatments in recent times, accompanied by a strong focus across health systems to increase early opinion and expanded patient access to treatments, has redounded in global spending on oncology medicines, reaching $164 billion in 2020 and an estimated $269 billion by 2025 indeed as periodic growth rates ease to about 10. Exhibition 52: Global oncology spending growth to exceed $260 billion by 2025, with growth decelerating to 9–12 from biosimilar savings.